A
A
Home

Clinical Trials

argenx has clinical trials ongoing across its differentiated antibody pipeline

Efgartigimod

Generalized Myasthenia Gravis (gMG)

ADAPT NXT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Primary Immune Thrombocytopenia (ITP)

ADVANCE

Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

ADVANCE SC

Phase 3 trial evaluating SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ADHERE

Phase 2 trial of SC Efgartigimod for the treatment of CIDP
Program: Efgartigimod

Pemphigus Vulgaris (PV)

Bullous Pemphigoid (BP)

Idiopathic Inflammatory Myopathies (Myositis)

Post-COVID Postural Orthostatic Tachycardia Syndrome (PC-POTS)

Primary Sjogren’s Syndrome (pSS)

RHO STUDY

Phase 2 trial of IV efgartigimod for the treatment of primary Primary Sjögren’s Syndrome
Program: Efgartigimod

ARGX-117

Multifocal Motor Neuropathy (MMN)

ARGX-117

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
Program: ARGX-117

More information
argenx MMN study website